Obesity Featured Articles

  1. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

  2. Receptor Occupancy In The Era Of Multispecific Therapeutics 8/21/2026

    Receptor occupancy studies face new challenges as multispecific therapeutics introduce complex target engagement, receptor trafficking, cellular interactions, and assay interpretation considerations.

  3. Sustainable Patient Engagement: Your Enrollment And Representation Depend On It 8/21/2026

    Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.

  4. 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint 8/21/2026

    Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.

  5. The Big Idea Behind The Creation Of SIP 8/20/2026

    Jackie Kent, Lisa Moneymaker, and Jeanette Teague were among the early architects of the Shared Investigator Platform (SIP). In part one of this four-part series, they discuss SIP’s ambitious origins, the challenges of getting competing sponsors to collaborate, and why broad adoption was critical to delivering on its promise of reducing site burden.

  6. The Reality Of Clinical Research Federal Funding Cuts 8/20/2026

    Although the most catastrophic federal funding cuts didn't come to fruition, Pamela Garzone discusses where some impacts are being felt now and will be felt for years to come.

  7. Building The Execution Architecture For Real-World Data To Have Real-World Impact 8/20/2026

    RWE's next challenge is execution. Learn how life sciences orgns can turn evidence into sustained business and clinical impact.

  8. Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial 8/20/2026

    Viral stock can make or break a norovirus challenge study. Cocrystal Pharma's Sam Lee explains why inoculum quality, infectivity, and availability matter.

  9. Running Compliant Studies Without Enterprise EDC Overhead 8/19/2026

    Low-complexity medical device and IVD studies often fall between enterprise EDC systems and spreadsheets. This webinar shows how a compliant, audit-ready alternative works in practice.

  10. From Hype To Health: The Three Jobs Sword Made Its Clinical Evidence Do 8/19/2026

    A long-term strategy for turning clinical evidence into clinician trust, standard-of-care status, and payer reimbursement for digital care.